登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>EGF R >EGR-H82E3

Biotinylated Human EGF R Protein, His,Avitag™ (MALS verified)

分子别名(Synonym)

EGFR,ERBB,ERBB1,HER1,PIG61,mENA

表达区间及表达系统(Source)

Biotinylated Human EGF R, His,Avitag (EGR-H82E3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 645 (Accession # P00533-1).

Predicted N-terminus: Leu 25

Request for sequence

蛋白结构(Molecular Characterization)

EGF R Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 72.3 kDa. The protein migrates as 100-115 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

EGF R SDS-PAGE

Biotinylated Human EGF R, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

EGF R SEC-MALS

The purity of Biotinylated Human EGF R, His,Avitag (Cat. No. EGR-H82E3) is more than 90% and the molecular weight of this protein is around 80-110 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

EGF R ELISA

Immobilized Cetuximab at 2 μg/mL (100 μL/well) can bind Biotinylated Human EGF R, His,Avitag (Cat. No. EGR-H82E3) with a linear range of 2-6 ng/mL (QC tested).

Protocol

EGF R ELISA

Immobilized Human EGF, Tag Free at 10 μg/mL (100 μL/well) can bind Biotinylated Human EGF R, His,Avitag (Cat. No. EGR-H82E3) with a linear range of 0.156-5 μg/mL (Routinely tested).

Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of biotinylated EGFR binding cell surface anti-EGFR scFv

EGF R CAR_T

Cells were transfected with anti-EGFR scFv and cultured for 3 days. Three days post-transfection, 1e6 cells were stained for anti-EGFR scFv with Biotinylated Human EGFR, His,Avitag (Cat. No. EGR-H82E3) followed by PE-conjugated streptavidin. Flow Cytometry assay shows that Biotinylated Human EGFR, His,Avitag (Cat. No. EGR-H82E3) can bind to cells expressing anti-EGFR scFv. The concentration of EGFR used is 0.8 µg/mL. (Data are kindly provided by Guangzhou Bio-gene Technology Co. Ltd.)

 

背景(Background)

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.

文献引用(Citations)

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
EGF R靶点信息
英文全称:Epidermal growth factor receptor erbB1
中文全称:表皮生长因子受体erbB1
种类:Homo sapiens
上市药物数量:31详情
临床药物数量:169详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定